These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 3855696)

  • 1. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.
    Daghestani AN; Arlin ZA; Leyland-Jones B; Gee TS; Kempin SJ; Mertelsmann R; Budman D; Schulman P; Baratz R; Williams L
    Cancer Res; 1985 Mar; 45(3):1408-12. PubMed ID: 3855696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
    Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
    Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia.
    Berman E; Raymond V; Daghestani A; Arlin ZA; Gee TS; Kempin S; Hancock C; Williams L; Stevens YW; Clarkson BD
    Cancer Res; 1989 Jan; 49(2):477-81. PubMed ID: 2910465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
    Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
    Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone in patients with acute leukemia in relapse.
    Paciucci PA; Ohnuma T; Cuttner J; Silver RT; Holland JF
    Cancer Res; 1983 Aug; 43(8):3919-22. PubMed ID: 6861154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral idarubicin in combination with cytosine-arabinoside in previously untreated patients with acute non-lymphocytic leukemia.
    Falkson G; Coccia-Portugal MA; Vorobiof DA; Terblanche AP; Dreyer R
    Am J Clin Oncol; 1986 Aug; 9(4):311-4. PubMed ID: 3463190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
    Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
    Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical studies with rubidazone.
    Benjamin RS; Keating MJ; Swenerton KD; Legha S; McCredie KB
    Cancer Treat Rep; 1979 May; 63(5):925-9. PubMed ID: 287557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
    Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary results in secondary acute non-lymphocytic leukemia (ANLL) treated with Idarubicin.
    Parmentier C; Finaud M; Schlumberger M; Morardet N; Berger R; Bayle C; Carde P; Hurteloup P; Hayat M
    Nouv Rev Fr Hematol (1978); 1985; 27(6):393-5. PubMed ID: 3867854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daunorubicin-prednisone in the treatment of acute nonlymphocytic leukemia.
    Peterson BA; Bloomfield CD; Theologides A; Kennedy BJ
    Cancer Treat Rep; 1981; 65 Suppl 4():29-33. PubMed ID: 6955011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
    Berman E; Wittes RE; Leyland-Jones B; Casper ES; Gralla RJ; Howard J; Williams L; Baratz R; Young CW
    Cancer Res; 1983 Dec; 43(12 Pt 1):6096-101. PubMed ID: 6580068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Ogawa M; Kimura I; Ohnoshi T; Yamada K; Masaoka T; Wakui A; Meguro S; Nagai K; Kitani T
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):3021-7. PubMed ID: 3464230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
    Hayat M; Hurteloup P; Parmentier C; Carde P; Pico JO; Schlumberger M; Chahine G; Kamioner D
    Invest New Drugs; 1984; 2(4):375-9. PubMed ID: 6595242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients.
    Lowenthal RM; Chesterman CN; Griffiths JD; Manoharan A; Harris MG; Herrmann RP; Rooney KF; Rozenberg MC; Salem HH; Wolf MM
    Cancer Treat Rep; 1987 Dec; 71(12):1279-81. PubMed ID: 3480044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early phase II study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group].
    Ogawa M; Masaoka T; Yamada K; Kimura K
    Gan To Kagaku Ryoho; 1993 May; 20(7):897-906. PubMed ID: 8489296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
    Park HS; Kim DW; Kim CC; Kim HK; Kim JS; Hwang TJ; Kim HJ; Kim HS; Song HS; Park JW; Ahn HS; Chung TJ; Cho KS; Lee KS; Choi YM
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):24-9. PubMed ID: 8916313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia.
    Madon E; Grazia G; De Bernardi B; Comelli A; Carli M; Sainati L; Paolucci G; Canino R; Colella R; Bagnulo S
    Cancer Treat Rep; 1987 Sep; 71(9):855-6. PubMed ID: 3476202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.